Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

BP C2

Drug Profile

BP C2

Alternative Names: Ammonium molybdate complexed with a lignin-derived polymer containing benzene polycarboxylic acids; BP-C2

Latest Information Update: 28 Nov 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Meabco
  • Class Antineoplastics; Heavy metals; Polyphenols; Radioprotectives
  • Mechanism of Action Free radical scavengers; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Chemotherapy-induced damage
  • Phase I Prostate cancer
  • No development reported Acute radiation syndrome; Radiation injuries

Most Recent Events

  • 28 Nov 2024 No recent reports of development identified for preclinical development in Acute-radiation-syndrome in Denmark (PO)
  • 28 Dec 2021 No recent reports of development identified for preclinical development in Radiation-injuries(Prevention) in Denmark (PO)
  • 15 Oct 2020 Meabco's technology platform BP-Cx-1 has patent protection worldwide

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top